HomeRGLS • NASDAQ
add
Regulus Therapeutics Inc
$8.22
Makalipas ang Oras ng Trabaho:(0.12%)-0.010
$8.21
Sarado: Hun 6, 5:42:27 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$8.10
Sakop ng araw
$8.07 - $8.28
Sakop ng taon
$0.83 - $8.28
Market cap
569.10M USD
Average na Volume
2.38M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 3.72M | 33.49% |
Net na kita | -9.63M | -13.76% |
Net profit margin | — | — |
Kita sa bawat share | -0.15 | 48.28% |
EBITDA | -10.45M | -19.53% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 65.37M | -32.99% |
Kabuuang asset | 74.83M | -34.44% |
Kabuuang sagutin | 5.80M | -11.48% |
Kabuuang equity | 69.03M | — |
Natitirang share | 69.23M | — |
Presyo para makapag-book | 7.79 | — |
Return on assets | -33.14% | — |
Return on capital | -35.63% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -9.63M | -13.76% |
Cash mula sa mga operasyon | -10.61M | -21.40% |
Cash mula sa pag-invest | 21.50M | 127.37% |
Cash mula sa financing | 45.00K | -99.95% |
Net change in cash | 10.93M | 87.87% |
Malayang cash flow | -6.34M | -1.31% |
Tungkol
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. In April 2025, Novartis announced that it had entered into an agreement to acquire Regulus. Wikipedia
Itinatag
Set 2007
Website
Mga Empleyado
34
